The ASH meeting included positive early results about a Terns drug for chronic myeloid leukemia and a Kura menin-blocker for ...
If any ambiguity remained about the ultimate goal of the current administration’s public health policy, last week shattered ...
Terns Pharmaceuticals reports its targeted leukemia drug maintained and even boosted molecular response rates in ...
Apparently, some vets are already using GLP-1s for diabetic cats. We are all a clinical trial or two away from “Ozempets” ...
From my colleague Elaine Chen: Wave Life Sciences said today that interim data show its investigational siRNA therapy cut ...
After two days of contentious discussion, federal vaccine advisers voted Friday in favor of a major change to childhood ...
An investigational GLP-1 pill from Structure Therapeutics led to substantial weight loss, but patients also had high rates of ...
And other pharma news rounded up from around the Pharmalot campus, as told to you by the Pharmalittle newsletter ...
Dyne Therapeutics plans to submit its next-gen Duchenne muscular dystrophy drug to the FDA after a successful trial.
Dispersing federal research funding, largely concentrated at private universities on the coasts, to the rest of the country ...
Medical professionals should look past the partisan framing and engage with the substance of this debate,” write the authors ...
Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback